Biomarker development in MET-targeted therapy

Yanni Zhang; Zhiqiang Du; Mingqiang Zhang

doi:10.18632/oncotarget.8276

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Biomarker development in MET-targeted therapy

Yanni Zhang, Zhiqiang Du and Mingqiang Zhang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:37370-37389. https://doi.org/10.18632/oncotarget.8276

Metrics: PDF 2172 views | HTML 21165 views | ?

Abstract

Yanni Zhang1, Zhiqiang Du1 and Mingqiang Zhang1

1 Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd, Shanghai, China

Correspondence to:

Mingqiang Zhang, email:

Keywords: MET, amplification, overexpression, biomarker, MET-targeted therapy

Received: September 18, 2015 Accepted: March 14, 2016 Published: March 22, 2016

Abstract

Activation of the MET receptor tyrosine kinase by its ligand, hepatocyte growth factor (HGF), has been implicated in a variety of cellular processes, including cell proliferation, survival, migration, motility and invasion, all of which may be enhanced in human cancers. Aberrantly activated MET/HGF signaling correlates with tumorigenesis and metastasis, and is regarded as a robust target for the development of novel anti-cancer treatments. Various clinical trials were conducted to evaluate the safety and efficacy of selective HGF/MET inhibitors in cancer patients. There is currently no optimal or standardized method for accurate and reliable assessment of MET levels, or other biomarkers that are predictive of the patient response to MET-targeted therapeutics. In this review, we discuss the importance of accurate HGF/MET signal detection as a predictive biomarker to guide patient selection for clinical trials of MET-targeted therapies in human cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8276

Publication Alerts

Reviews:

Biomarker development in MET-targeted therapy

Abstract